G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
04 Abril 2024 - 8:30AM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology
company, today announced that G1’s Chief Executive Officer Jack
Bailey will provide a corporate presentation during the 23rd Annual
Needham Virtual Healthcare Conference on Thursday, April 11, 2024,
at 8:45 AM ET.
The webcast of the event will be accessible on the Events &
Presentations page of https://www.g1therapeutics.com/.
About G1 TherapeuticsG1 Therapeutics, Inc. is a
commercial-stage oncology biopharmaceutical company whose mission
is to develop and deliver next-generation therapies that improve
the lives of those affected by cancer, including the Company’s
first commercial product, COSELA® (trilaciclib). The Company is
also evaluating therapies in combination with cytotoxic therapies
and/or immunotherapy in areas of high unmet need including
triple-negative breast cancer and extensive stage small cell lung
cancer. G1’s goal is to provide innovative therapeutic advances for
people living with cancer. G1 is based in Research Triangle Park,
N.C. For additional information, please visit
www.g1therapeutics.com and follow us on X (formerly known as
Twitter) @G1Therapeutics and LinkedIn.
G1 Therapeutics® and the G1 Therapeutics logo
and COSELA® and the COSELA logo are trademarks of
G1 Therapeutics, Inc.
Contact:Will RobertsCommunications OfficerVice
President, Investor Relations & Corporate Communications(919)
907-1944 wroberts@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
G1 Therapeutics (NASDAQ:GTHX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024